Ascend Wellness (AAWH) Q3 2024 earnings summary

Executive summary

• Leadership transition completed, with a new CEO and CFO focused on operational efficiency, cost control, and growth.

• Strategic shift from hyper-growth to optimizing existing assets for sustainable profitability.

• Vertically integrated operator with assets in seven states, 39 dispensaries, and 255,000 sq. ft. of canopy.

• Transformation initiatives target $30 million in annual savings for 2025, including a 15% reduction in corporate and 10% in retail/operations headcount.

• Adult-use sales in Ohio drove significant retail revenue growth, with sales tripling post-transition.

Financial highlights

• Q3 2024 net revenue was $141.6 million, up 0.3% year-over-year and 0.1% sequentially.

• Adjusted EBITDA was $25.1 million with a 17.7% margin, down 15% year-over-year and 11.4% sequentially.

• Retail revenue was $93.6 million, down 7.6% year-over-year but up 0.6% sequentially; wholesale revenue was $48.0 million, up 20.1% year-over-year but down 0.8% sequentially.

• Gross profit was $43.7 million (30.9% margin); adjusted gross profit was $53.6 million (37.8% margin).

• Ended Q3 with $65.3 million in cash and $240.6 million in net debt.

Outlook and guidance

• Management expects $30 million in annual cost savings from transformation initiatives in 2025.

• Q4 revenue and adjusted EBITDA expected to be flat or slightly down sequentially.

• Six additional dispensaries in the pipeline, with further densification planned via partnerships.

• Focus remains on margin improvement, cost control, and vertical integration.

• Anticipates regulatory catalysts, including DEA rescheduling and DOJ case developments in 2025.